How to access Mavyret from Pakistan, the named-patient import pathway, 2026

By Reserve Meds, Clinical and regulatory team. Last reviewed 2026-05-13.

A Pakistani patient with chronic hepatitis C virus (HCV) genotypes 1 through 6 in adults and paediatric patients aged 3 years and older, with or without compensated cirrhosis may receive a prescription for Mavyret (glecaprevir and pibrentasvir) from their treating hepatologist or infectious disease physician. Mavyret is FDA-approved in the United States and manufactured by AbbVie. It is a pan-genotypic direct-acting antiviral fixed-dose combination administered by oral tablet. Local availability of Mavyret in Pakistan can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through DRAP remains a legitimate route for the patient whose physician has already prescribed the drug.

This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.

The clinical situation

Mavyret is a pan-genotypic direct-acting antiviral fixed-dose combination. Mechanism: glecaprevir inhibits HCV NS3/4A protease and pibrentasvir inhibits HCV NS5A; the fixed-dose combination is pan-genotypic. Dosing: three 100 mg/40 mg tablets (300 mg glecaprevir and 120 mg pibrentasvir) once daily by mouth with food, for 8 to 16 weeks depending on treatment history and cirrhosis status, per FDA labeling. Baseline workup per FDA labeling includes HCV RNA quantification, genotype where available, fibrosis assessment, hepatitis B serologies (HBsAg, anti-HBc), and renal and hepatic function. The FDA boxed warning covers hepatitis B virus reactivation in HCV/HBV co-infected patients. Other important warnings include hepatitis B virus reactivation in HCV/HBV co-infected patients, and not recommended for patients with decompensated cirrhosis (Child-Pugh B or C). Your specialist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.

Is Mavyret legally importable into Pakistan?

Yes, through the Drug Regulatory Authority of Pakistan (DRAP) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Pakistan has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.

The DRAP named-patient route allows a Pakistani-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.

How the pathway works, step by step

  1. Consultation with your treating specialist. The prescribing decision is clinical. Your specialist documents the indication, prior therapies where relevant, and rationale for Mavyret.
  2. Baseline screening. HCV RNA quantification, genotype where available, fibrosis assessment, hepatitis B serologies (HBsAg, anti-HBc), and renal and hepatic function are confirmed and documented.
  3. DRAP named-patient application. Your specialist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
  4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from AbbVie's authorised distribution under DSCSA chain-of-custody.
  5. Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your specialist initiates therapy.

What documentation your physician needs

Your physician will typically need to provide:

  • A clinical rationale letter confirming diagnosis, prior therapies where relevant, and Mavyret as the indicated next step
  • Verification of their Pakistani medical licence
  • A patient identifier, anonymised reference where privacy is preferred
  • Documented pre-treatment screening consistent with FDA labeling (see above)
  • The planned dosing regimen (three 100 mg/40 mg tablets (300 mg glecaprevir and 120 mg pibrentasvir) once daily by mouth with food, for 8 to 16 weeks depending on treatment history and cirrhosis status, per FDA labeling)
  • A monitoring plan covering HBV reactivation risk screen, fibrosis stage, and prior treatment history

Reserve Meds provides a physician documentation kit tailored for HCV direct-acting antiviral therapies, including the templates DRAP reviewers commonly request.

Typical costs and indicative timing

Reserve Meds gives you a drug-only reference range plus a transparent delivered quote at intake. As an illustrative composite case, the US cash-pay reference range for a typical 8 to 16 week treatment course of Mavyret sits in an indicative 2026 band of approximately USD 13,000 to 26,000. International logistics, DRAP documentation handling, and concierge coordination add incremental cost. The delivered quote we issue at intake shows each line separately.

Indicative timing for first dose after cohort intake opens is approximately 2 to 5 weeks from the moment a complete application is submitted, assuming the documentation package is clean on first pass. Refills ship on a rolling cadence aligned to the dosing schedule.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort. All timelines are indicative, not guarantees.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Mavyret specifically, we provide:

  • Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
  • Documentation. Regulatory package tailored for your physician and for DRAP review, including HCV direct-acting antiviral class templates.
  • Logistics. Internationally tracked shipment to your named dispensing facility with tamper-evident packaging.
  • Concierge case lead. A named point of contact for your family and your physician across the full case arc.

We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating specialist, and dispensing sits with the licensed Pakistani pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.

Frequently asked

Is this legal in Pakistan? Yes, when executed through the DRAP named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Pakistani tertiary centers.

What about the boxed warning? The FDA boxed warning on Mavyret covers hepatitis B virus reactivation in HCV/HBV co-infected patients. Your specialist performs the risk-benefit assessment, schedules monitoring, and counsels the patient per labeling. Reserve Meds does not make that clinical judgement, your physician does.

Will my private health insurance cover this? Cash-pay is the default posture. Cash-pay is the default posture in Pakistan; some employer plans cover specialty imports case-by-case. We supply documentation for your submission but do not process insurance claims.

What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Pakistani tertiary centers (Shaukat Khanum Memorial Cancer Hospital, Aga Khan University Hospital, and the Indus Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what DRAP reviewers commonly ask for.

Join the waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Mavyret coordination in Pakistan.

Add me to the Mavyret waitlist

Composite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice. Reserved for you.